StockData
Inhibrx Biosciences, Inc. logo

Inhibrx Biosciences, Inc. (INBX) stock

INBXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 1/30
$74.18−3.48 (-4.48%)

Close on Nov 17, 2026Market cap $1.09BP/E –Yield –

Inhibrx Biosciences total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Inhibrx Biosciences's total debt was $276.70M at Sep 30, 2026. For fiscal 2025 it was $100.56M. The highest annual figure on record is $206.97M in fiscal 2023.

Annual total debt

PeriodPeriod endValueChange
FY2025Dec 31, 2025$100.56M–
FY2024Dec 31, 2024$0-100.0%
FY2023Dec 31, 2023$206.97M–
FY2020Dec 31, 2020$0-100.0%
FY2019Dec 31, 2019$3.56M–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$276.70M+176.9%
Q2 FY2026Jun 30, 2026$176.29M+77.6%
Q1 FY2026Mar 31, 2026$174.99M+77.4%
Q4 FY2025Dec 31, 2025$100.56M–
Q3 FY2025Sep 30, 2025$99.92M–
Q2 FY2025Jun 30, 2025$99.28M–
Q1 FY2025Mar 31, 2025$98.65M-52.6%
Q4 FY2024Dec 31, 2024$0-100.0%
Q3 FY2024Sep 30, 2024$0–
Q2 FY2024Jun 30, 2024$0-100.0%
Q1 FY2024Mar 31, 2024$208.21M+5743.7%
Q4 FY2023Dec 31, 2023$206.97M–
Q4 FY2020Dec 31, 2020$0–
Q3 FY2020Sep 30, 2020$1.88M–
Q4 FY2019Dec 31, 2019$3.56M–

More Inhibrx Biosciences figures

See a number that looks wrong?